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Background: The potential need for an ostomy is a main concern for patients with inflammatory bowel disease. We performed this study to evaluate
the impact of a long-term ostomy ($6 mo duration) on the functional status and specific patient-reported outcomes in a population of patients with
Crohn’s disease (CD).
Methods: We performed a cross-sectional analysis within the Crohn’s and Colitis Foundation of America Partners cohort. Bivariate analyses and
logistic regression models were used to investigate associations between ostomy and various demographic, disease factors, and patient-reported outcomes
for health-related quality of life.
Results: A total of 402 CD patients with ostomy for a minimum duration of 6 months were compared with 4331 CD patients with no ostomy. Patients
with ostomy were more likely to be in clinical remission compared with those without ostomy, 48.5% versus 31.3%, respectively. Having an ostomy did
not impact the overall health-related quality of life and was not associated with anxiety, depression, sleep disturbances, or reduced sexual interest and
satisfaction. However, the presence of ostomy was associated with reduced social role satisfaction in both patients with controlled and active disease.
Additionally, in the subset of patients who did not achieve clinical remission, those with ostomy experienced greater pain interference (odds ratio, 1.63;
95% confidence interval, 1.12–2.35) and fatigue (odds ratio, 1.66; 95% confidence interval, 1.15–2.39).
Conclusions: Ostomy is well tolerated in CD patients, particularly when clinical remission is achieved.
(Inflamm Bowel Dis 2016;22:2658–2664)
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D espite the recent advances in medical therapies, patientswith Crohn’s disease (CD) continue to require surgical
interventions at a high rate, with an estimated lifelong likeli-
hood of surgery of up to 80%.1 This frequently entails the
creation of either a temporary or a permanent stoma. Approx-
imately 10% of CD patients will need a permanent stoma at
a certain stage of their disease course.1 The potential need for
an ostomy is among the top concerns for patients with inflam-
matory bowel disease (IBD).2–7 This concern has been noted to
be independent of disease subtype and severity and persisted
when patients were assessed longitudinally over a 1-year
period.7 Nevertheless, data about the actual impact of ostomy
on functional status and health-related quality of life (HRQOL)
of IBD patients are very limited. Furthermore, IBD patients
with ostomies are frequently excluded from clinical research
because many of the tools used to assess disease activity and
HRQOL do not apply to this subpopulation (e.g., questions on
bowel movement frequency).
Few studies have linked having a stoma to a number of
adverse psychosocial outcomes including depression and anxi-
ety, increased loneliness, lowered self-esteem, poorer body
image, and sexual disturbances.8–11 However, the majority of
these studies were qualitative in nature and were not restricted
to IBD patients. In fact, 2 of the above-referenced studies were
in non-IBD patients who required an ostomy for an underlying
malignancy.9,11 IBD patients who frequently suffer from severe
and refractory disease before proceeding with a surgery may
perceive living with an ostomy differently. For example, in
a study by Nordin et al12 evaluating HRQOL and psychosocial
distresses in 492 IBD patients, of which 67 (14%) reported an
ileostomy, patients with ileostomy had better social functioning,
emotional functioning, and fewer bowel symptoms compared
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with those with ileoanal anastomosis. Furthermore, when com-
pared with patients without ileostomy but with comparable dis-
ease extent, patients with ileostomies had similar levels of
HRQOL and comparable anxiety and depression scores to those
with no ileostomy.
In this study, we aimed to assess the subset of CD patients
within the Crohn’s and Colitis Foundation of America (CCFA)
Partners cohort study who had an ostomy for a minimum duration
of 6 months as compared with those patients with CD and no
ostomy and to investigate the impact of ostomy on specific
patient-reported outcomes (PROs) including anxiety, depression,
fatigue, pain interference, sleep disturbances, social satisfaction,
and sexual interest and satisfaction.
MATERIALS AND METHODS
Study Design
We performed a cross-sectional analysis of a subset of CD
patients within the CCFA Partners cohort who had an ostomy for
a minimum duration of 6 months.
Study Population
CCFA Partners is a longitudinal Internet-based cohort of
adult IBD patients, which has been ongoing since 2011. The
development of the cohort has been previously described.13 In
brief, after a baseline survey, participants are invited to com-
plete follow-up surveys every 6 months. At baseline and at
each follow-up interval, data on demographics, disease subtype
and characteristics, medications, measures of disease activity,
and various PROs are collected. All data are self-reported.
Within this cohort, we identified our study population as all
CD patients completing 2 surveys 6 or more months apart who
reported either having or not having an ostomy at both time
points (N ¼ 4733).
Study Variables
Disease activity was assessed using the Manitoba IBD
Index (MIBDI). MIBDI is a validated, single-item, patient-
defined, disease activity measure.14 Patients are asked to select
the statement that best describes their disease activity over the past
6 months from these categories: (1) constantly active, giving me
symptoms every day; (2) often active, giving me symptoms most
days; (3) sometimes active, giving me symptoms on some days
(for instance 1–2 d/wk); (4) occasionally active, giving me symp-
toms 1 to 2 d/mo; (5) rarely active, giving me symptoms on a few
days in the past 6 months; and (6) I was well in the past 6 months,
what I consider a remission or absence of symptoms. Patients with
any of (1–4) answers are considered to have active disease,
whereas those choosing answers 5 or 6 are considered to be in
clinical remission. The short IBD Questionnaire (SIBDQ) (Short
Inflammatory Bowel Disease Questionnaire [SIBDQ] was auth-
ored by Dr. J. Irvine, et al, was made under license from McMas-
ter University, Hamilton, Canada) was used to assess HRQOL.
For each participant, levels of anxiety, depression, fatigue, sleep
disturbances, pain interference, social satisfaction, and sexual
interest and satisfaction were assessed using the Patient-
Reported Outcomes Measurement Information System
(PROMIS). The PROMIS measures have been previously vali-
dated in general and in chronically ill populations, and their per-
formance has also been assessed within the CCFA Partners
cohort.15–17 In brief, participants completed 2 to 4 items for each
of the PROMIS domains. The items are then calibrated using
t-score metric to provide a mean value for the domain assessed,
where higher scores indicates higher level of the domain being
measured (e.g., more anxiety or more social satisfaction). In the
generally healthy populations, the mean t-score for anxiety,
depression, fatigue, pain interference, sleep disturbances, and
social satisfactions is 50 with standard deviation (SD) of 10. A
priori thresholds of $52 (anxiety, depression, fatigue, pain inter-
ference, and sleep disturbances) and #48 (social satisfaction)
were selected to define the presence of an adverse PRO within
each domain. We chose these threshold cut points to allow for
a clinically meaningful separation from the general population.
Minimal important differences in PROMIS measures for IBD
patients have not been defined. However, in cancer patients,
chronic pain patients and healthy pediatric patients, research has
revealed a range of minimal important differences of 2 to 6 for
several of the PROMIS domains.18–20 The mean t-scores within
the general population for the domains of sexual interest and
satisfaction are gender specific: 50 (10) in men and 42 (14) in
women for sexual interest and 51 (9) in men and 49 (11) in
women for sexual satisfaction.21
Statistical Analysis
Descriptive statistics were used to describe the demo-
graphic and disease-related characteristics of the studied
population stratified by the presence or absence of ostomy.
Continuous variables were presented as mean and SD, whereas
the categorical variables were reported as percentages. We
performed statistical tests of group differences using Pearson’s
chi-square test for categorical variables and Student’s t-tests for
continuous variables. Within strata defined by disease activity,
multivariable logistic regression models were then used to
investigate independent associations between ostomy status
and anxiety, depression, fatigue, pain interference, sleep dis-
turbances, and social satisfaction while controlling for partic-
ipants’ age, body mass index, disease duration, gender,
smoking status, and IBD therapies. The main outcomes of
interest in these logistic models were the presence of adverse
PROs defined as mean $ 52 for anxiety, depression, fatigue,
pain interference, and sleep disturbances and #48 for social
satisfaction. One-way between-groups analysis of covariance
was used to assess the impact of having an ostomy on sexual
interest and satisfaction while controlling for the participant’s
age and disease activity. We also used logistic regression mod-
eling to assess predictors of narcotic use. All statistical analy-
ses were performed using SPSS version 22.0 (IBM, Corp,
Armonk, NY).
Ethical Considerations
The Institutional Review Board at the University of North
Carolina approved the study protocol.
RESULTS
Patient Characteristics
A total of 4733 CD patients were included in the study. Of
these, 402 patients (8.5%) reported an ostomy on both their
baseline and first follow-up surveys (minimum duration of 6
months). Patients with ostomy were older (mean age, 49.3 years)
and had longer disease duration (mean, 26.2 months) compared
with those with no ostomy (mean age, 43.7 years and mean
disease duration, 15.1 months). Both groups were comparable in
regard to race and gender distributions, body mass index, and the
proportion of current smokers (Table 1). As measured by the
MIBDI, more patients with ostomy were in clinical remission
compared with those without ostomy (48.5% for ostomy versus
31.3% for no ostomy; P , 0.001).
The frequencies of IBD medications use by patients with and
without ostomies are shown in Table 1. Overall, patients with
ostomies were less likely to use IBD medications than those with-
out ostomies (50% versus 65%; P , 0.001). The majority of
ostomy patients treated with medications reported the use of a bio-
logic agent (40.5%) or an immunomodulator (56.9%). A total of
13.6% patients with ostomy reported being on 5-aminosalicylate
therapy. The rate of systemic corticosteroid use was similar for
patients with and without ostomy (12.8% versus 15.3%; P ¼ 0.21).
Interestingly, narcotic use was higher among patients with
an ostomy as compared with those without ostomy (21.5% versus
14.7%; P ¼ 0.001). Using logistic regression modeling to assess
independent predictors for narcotic use among the study popula-
tion while controlling for disease activity and several demo-
graphic and disease-related characteristics, having an ostomy
was an independent predictor for narcotic use (odds ratio [OR],
1.68; 95% confidence interval [CI], 1.24–2.27). Other predictors
included in the model are listed in Table 2.
Impact of Ostomy on Quality of Life and PROs
Because disease activity is likely to influence the HRQOL
and the various PROs, the impact of ostomy on these outcomes
was examined within strata defined by disease activity. On
bivariate analysis, the HRQOL as assessed by the SIBDQ was
comparable for patients with and without ostomy within each
strata of disease activity (Table 3). Among those in clinical remis-
sion, the scores for all 6 PROMIS domains (anxiety, depression,
fatigue, pain interference, sleep disturbances, and social satisfac-
tion) were comparable in patients with and without ostomy. How-
ever, for patients whose disease activity is not controlled, those
with ostomy had worse PROMIS scores for fatigue, pain interfer-
ence, and social satisfaction compared with those with no ostomy
(Table 3). Using logistic regression models to investigate inde-
pendent (adjusted) associations between ostomy and the 6 PROs
within strata defined by disease activity, having an ostomy was
noted to be an independent predictor for fatigue (OR, 1.66; 95%
CI, 1.15–2.39), pain interference (OR, 1.63; 95% CI, 1.12–2.35),
and reduced social satisfaction (OR, 1.42; 95% CI, 1.03–1.95)
among patients with active disease. Conversely, among those
who were in clinical remission, ostomy was only associated with
reduced social satisfaction (OR, 1.68; 95% CI, 1.19–2.38) but
none of the other assessed outcomes (Fig. 1).
For patients who completed the sexual function domains
(n ¼ 1326 for sexual interest domain and n ¼ 991 for sexual
satisfaction domain), mean scores for sexual interest and
TABLE 1. Demographic and Disease-Related








(n ¼ 402) Pa
Age, yr 43.7 (15) 49.3 (14) ,0.001
Women 72.9 71.8 0.64
White race 95.0 95.1 0.79
Body mass index, kg/m2 25.6 (6) 26.2 (6) 0.06
Current smoker 6.6 8.0 0.29
Disease duration, yr 15.1 (13) 26.2 (14) ,0.001
Remission per MIBDI 31.3 48.5 ,0.001
Systemic steroid 15.3 12.8 0.21
5-Aminosalicylates 35.9 13.6 ,0.001
Immunomodulator therapy 31.3 28.4 0.25
Biologic therapy 42.2 33.6 0.001
Narcotic 14.7 21.5 0.001
Any IBD medication 64.7 49.9 ,0.001
Data presented at mean (SD) or percentages.
aComparisons were made using Pearson’s chi-square test for categorical variables and
Student’s t-test for continuous variables.
TABLE 2. Predictors of Narcotic Use Among the Study
Population, Based on a Logistic Model Including All
Predictors
Variable Odd Ratio 95% Confidence Interval
Remission per MIBDI 0.64 0.49–0.83
Current ostomy 1.68 1.24–2.27
Current smoker 1.60 1.19–2.16
Current age 1.02 1.01–1.02
Female gender 0.97 0.78–1.20
Pain interferencea 1.13 1.12–1.15
aPresence of pain interference was defined as PROMIS mean score of $52.
satisfaction were similar in both patients with and without
ostomy, which remained true after adjusting for age and dis-
ease activity (Table 4).
DISCUSSION
The potential need for an ostomy is a major concern for
patients with IBD, particularly CD patients who may be at higher
risk of needing a permanent ostomy. Nevertheless, up until now,
the data on the actual impact of having an ostomy in this
population were very limited. In this large sample of CD patients,
we analyzed the demographic and disease-related characteristics
of patients with ostomy for a minimum duration of 6 months
compared with those without ostomy. Furthermore, we investi-
gated the impact of having an ostomy on several PROs pertaining
to different functional and psychosocial domains. We observed
several important findings. First, as expected, patients with
ostomy were older and had longer disease duration compared
with those without an ostomy. This is likely a reflection of the
general notion that surgery is reserved as a last resort for patients
with CD after failing several medical therapies.
Second, patients with an ostomy were more likely to be in
clinical remission compared with those without an ostomy (48.5%
versus 31.3%, respectively). This is mirrored by the observation
TABLE 3. Patient-Reported Outcomes by Ostomy Status, Stratified by MIBDI-Defined Disease Activity
Patient-Reported Outcome
MIBDI-Defined Active Disease MIBDI-Defined Remission
No Ostomy (n ¼ 2948) Ostomy (n ¼ 205) No Ostomy (n ¼ 1344) Ostomy (n ¼ 193)
HRQOL (SIBDQ) 4.5 (1.1) 4.7 (1.1) 5.8 (0.8) 5.8 (0.8)
Anxiety (PROMIS) 54.2 (9.5) 54.7 (9.9) 49.2 (8.8) 49.4 (9.1)
Depression (PROMIS) 52.6 (9.5) 53.5 (10.0) 47.4 (8.0) 48.5 (8.9)
Fatigue (PROMIS) 58.3 (10.4) 59.8 (10.8)a 49.8 (9.8) 49.8 (10.4)
Pain interference (PROMIS) 55.2 (9.5) 57.8 (9.5)a 46.3 (7.6) 46.7 (8.3)
Sleep disturbances (PROMIS) 52.0 (3.5) 52.1 (3.5) 52.0 (3.3) 52.3 (3.6)
Social satisfaction (PROMIS) 46.3 (9.2) 44.3 (9.2)a 53.0 (9.3) 51.7 (9.9)
All values are mean (SD) of the relevant PRO.
aP value of #0.05 for Student’s t-test.
FIGURE 1. The impact of having an ostomy on PROs among patients with clinically active disease (A) and patients in clinical remission (B). A
separate logistic regression model was applied for each outcome. The models controlled for gender, age, disease duration, smoking status, current
corticosteroid, biologic, and immunomodulator therapies.
needed to understand the nature of pain in CD patients with
ostomy and provide appropriate alternatives to narcotic-based
analgesia in this population.
In our study, having an ostomy did not impact HRQOL as
measured by SIBDQ. Although SIBDQ is an IBD-specific quality
of life (QOL) measure, it is important to note that this
questionnaire has not been separately validated in patients with
ostomy. Hence, our results should be interpreted in the context of
this limitation. Nevertheless, our findings are comparable to
results from 2 previous studies that used a generic QOL tool,
the Short Form 36 (SF-36) questionnaire, to assess the impact of
ostomy on HRQOL among IBD patients.12,27 In both studies,
ostomy did not have a significant impact on HRQOL.
In regards to the 6 assessed PROMIS domains, having an
ostomy seems to primarily impact social satisfaction given our
observed association between ostomy and reduced social satis-
faction irrespective of active/remission disease status. This impact
of ostomy on social satisfaction may be related to an altered body
image and the technical issues related to daily ostomy care. In
a study by Carlsson et al,27 the Rating Form of IBD Patients
Concerns questionnaire was used to assess the concerns of pa-
tients with ileostomy. Producing unpleasant odor and being a bur-
den on others were among the top 5 concerns, both of which can
impact social functioning and satisfaction. We also observed sig-
nificant associations between ostomy status and both fatigue and
pain interference among patients with clinically active disease but
not for those in clinical remission. It is unclear whether these
associations represent a causal effect of ostomy in this population
or, alternatively, ostomy serves as a surrogate marker for more
severe and complicated disease with resultant pain and fatigue in
patients who continue to have active disease despite prior surgical
intervention. At a more reassuring note, having an ostomy did not
impact anxiety, depression, or sleep disturbances scores even in
patients with active disease, and ostomy was not associated with
pain interference or fatigue among those in remission.
Finally, in our study population, having an ostomy did not
impact sexual interest or satisfaction in both men and women,
even after adjusting for age and disease activity. This is contrary
TABLE 4. Age-Adjusted and Disease Activity–Adjusted Means of PROMIS Scores for Sexual Interest and
Satisfaction Among Patients with and Without Ostomy Stratified by Gendera
Gender Sexual Function Domain
Patients Without Ostomy Patients with Ostomy
P (1-Way ANCOVA)Adjusted Mean (SE) Adjusted Mean (SE)
Men Sexual interest (n ¼ 270) 48.7 (0.6) 48.5 (1.7) 0.91
Sexual satisfaction (n ¼ 280) 48.2 (0.4) 46.1 (1.5) 0.17
Women Sexual interest (n ¼ 956) 40.4 (0.4) 40.8 (1.3) 0.77
Sexual satisfaction (n ¼ 711) 46.7 (0.3) 47.5 (1.1) 0.5
aThe general population mean (SD) for sexual interest are 50 (10) in men and 42 (14) in women and sexual satisfaction are 51 (9) in men and 49 (11) in women.
ANCOVA, analysis of covariance.
that only half of the patients with ostomy reported being on any 
IBD therapy. For CD patients, in whom the disease can involve 
any part of the gastrointestinal tract, surgery is not considered or 
advocated as a cure. However, those with primarily colonic 
disease have higher chances of maintaining long-term clinical 
remission after colectomy with a suggested advantage of ileos-
tomy over anastomosis.22,23 In a study by Bernell et al,22 the 
cumulative 10-year risk of a symptomatic recurrence after colec-
tomy with ileorectal anastomosis was 58% compared with 24%
after colectomy with ileostomy. The outcome is likely different 
for patients requiring ostomy for other indications, particularly 
those with refractory perianal disease. Our sample likely includes 
patients who received their ostomy for multiple indications.
Despite the higher prevalence of clinical remission, patients 
with ostomy were more likely to report narcotic use compared 
with those without ostomy (21.5% versus 14.7%, respectively). 
The higher rate of narcotic use in patients with ostomy persisted 
even among patients reporting remission based on the MIBDI 
(9.7% in patients with ostomy versus 5.5% in patients without 
ostomy). Furthermore, in the logistic regression modeling, having 
an ostomy was an independent predictor for narcotic use after 
controlling for age, gender, disease activity, smoking status, and 
pain interference. Within the CCFA Partners cohort, patients are 
not asked to specify which narcotic agents they are using. Hence, 
it is possible that the higher rate of narcotic use among patients 
with ostomy in our study is related to using this class of therapy to 
reduce ostomy output (e.g., tincture of opium) rather than 
managing pain. However, ostomy patients with active disease 
had a much higher prevalence of narcotic use compared with 
those with ostomy but in remission (32.5% versus 9.7%, 
respectively) and also compared with nonostomy patients with 
active disease (19%), suggesting that narcotic may be used to 
control disease symptoms in a significant proportion of patients 
with ostomy. This is further supported by the noted association 
between narcotic use and pain interference scores (Table 2). Nar-
cotic use in IBD patients has been linked to a number of adverse 
effects, including higher rate of infectious complications, surgical 
complications, and even mortality.24–26 Thus, further research is
to what has previously been reported in the literature as having an
ostomy was linked to a number of adverse physiological and
psychological effects that can impact sexual function in both men
and women. Among those effects are erectile dysfunction;
retrograde ejaculation; orgasmic dysfunction; dyspareunia; and
reduced sexual desire.28,29 The discrepancy between our results
and the prior literature is likely related to the indication for the
ostomy, IBD, rather than malignancy. This is particularly true for
the physiological effects resulting from nerve damage caused by
more extensive surgical resection and manipulation needed for
cancer resections but not typically for IBD-related surgeries. It
is also important to note that a smaller proportion of patients
completed the sexual function modules in our study, which may
have an impact on the power of our results.
There are several strengths to this study. It is, to our
knowledge, the largest to date to assess the characteristics of CD
patients with ostomy and investigate its impact on several PROs.
Furthermore, the studied population was part of a well-maintained
and geographically diverse cohort of IBD patients. In a validation
study from a subset of participants in the parent cohort, there was
a 97% accuracy rate of self-reported IBD status and disease
subtypes when compared with medical records.30 The use of val-
idated scales to assess a wide variety of clinically relevant PROs
is also a strength of this study. Finally, using the MIBDI, we were
able to conduct analyses stratified by disease activity in both
patients with and without ostomy.
We also recognize a number of limitations to our study. We
were unable to determine the indication for having an ostomy in
each patient, the exact time since surgery, and whether the ostomy
is permanent or temporary. In addition, the disease location and
behavior could not be specified for each patient. These character-
istics may influence how patients perceive the impact of having an
ostomy on their QOL. To mitigate this limitation and minimize the
variability, we only analyzed patients who reported the same
ostomy status in 2 subsequent surveys, and we used the responses
in the second survey to assess the impact on the various PROs. A
second limitation is the use of SIBDQ to assess HRQOL. As we
pointed out earlier, the SIBDQ is not validated in ostomy patients.
Furthermore, one item in the questionnaire is not applicable to
patients with ostomy (pertaining to tenesmus). Several stoma-
specific QOL questionnaires were proposed in the past.31–33 Those
questionnaires are relatively long (20–34 items), and none of them
is specific for IBD patients; hence, we elected to use the SIBDQ.
The relatively smaller proportion of patients completing the sexual
function modules is another limitation because we were unable to
use regression modeling to control for multiple variables in a man-
ner similar to our analyses of the other PROs. Nevertheless, we
were able to control for age and disease activity in our calculations,
both are expected to have greater impact on sexual function.
In conclusion, in this cross-sectional study of CD patients,
having an ostomy did not impact the QOL or sexual function of
the patients. Moreover, ostomy was not associated with anxiety,
depression, or sleep disturbances. The majority of ostomy-adverse
PROs associations, with the exclusion of social satisfaction, were
only observed in patients with active disease. Therefore, it is
reassuring that the presence of an ostomy concomitant with
controlled disease does not impact important PROs. These data
will aid in counseling individuals facing a surgical need for
temporary or permanent stoma creation.
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